Century Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $302.49M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | – | $-0.17 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | – | $-0.11 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | $-0.40 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | – | $-0.38 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | $109.20M | $0.89 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | Before market open | $800.00K | $-0.37 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Nov 5, 2024, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| generally accepted accounting principles (GAAP) operating expensesGAAP | full year | $150.00M to $160.00M | – |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Century Therapeutics filed with the SEC
CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CNTY - 813: Scalable Production of Allo - Evasion TM 5.0 - Engineered iPSC Islets for Off - the - Shelf Cell Therapies G. Grant Welstead, PhD SVP, Head of Research
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Joseph Truitt to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Century Therapeutics Reports Second Quarter 2026 Financial
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
New CNTY-813 Preclinical Data Demonstrate Durable
Other events · EX-99.1 to Form 8-K
Scalable Production of Allo-Evasion 5.0-
Other events · EX-99.2 to Form 8-K
Century Therapeutics Reports First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Century Therapeutics Reports Full Year 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
All statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to,
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Unlocking the Value of our Pipeline for T1D January 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
All statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to,
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Corporate Deck – December 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Century Therapeutics Appoints Accomplished Biotechnology
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Century Therapeutics Reports Third Quarter 2025
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Advancing Pipeline of Transformative Cell Therapies Corporate Deck – November 2025
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Century Therapeutics Announces New Beta Islet
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Century Therapeutics Reports Second Quarter
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
CNTY - 101 CAR - iNK cell therapy with Allo - Evasion 1.0
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Century Therapeutics Reports First Quarter 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
All statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to,
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Century Therapeutics Reports Full Year 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CNTY - 101 CAR - iNK cell therapy with Allo - Evasion 1.0
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Century Therapeutics Reports Third Quarter 2024
Results of operations · Other events · EX-99.1 to Form 8-K
Overview of foundational platform technologies
Results of operations · Other events · EX-99.2 to Form 8-K
Century Therapeutics Reports Second Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Overview of Foundational Platform Technologies
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Overview of Foundational Platform Technologies
Other events · EX-99.1 to Form 8-K
Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
Other events · EX-99.1 to Form 8-K
Overview of Foundational Platform Technologies
Other events · EX-99.2 to Form 8-K
Century Therapeutics Reports First Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition
Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Overview of Foundational Platform Technologies
Other events · EX-99.1 to Form 8-K
Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer
Other events · EX-99.1 to Form 8-K
Century Therapeutics Reports Full Year 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
and made pursuant to the safe harbour provisions of, The Private Securities
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential
Other events · EX-99.1 to Form 8-K
Initial Data from Phase 1 ELiPSE-1 Trial
Other events · EX-99.2 to Form 8-K